{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Yttrium_Y-90_Ibritumomab_Tiuxetan",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A radioimmunotherapeutic agent consisting of a murine monoclonal anti-CD20 antibody (ibritumomab) linked by the chelator tiuxetan to the radioisotope yttrium-90 (Y 90).  Yttrium Y 90 ibritumomab tiuxetan binds to and specifically delivers beta radiation to CD20-expressing tumor cells, thereby minimizing the systemic effects of radiation.",
    "fdaUniiCode": "QA846JAV5B",
    "identifier": "C1812",
    "preferredName": "Yttrium Y-90 Ibritumomab Tiuxetan",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C129819",
      "C1511"
    ],
    "synonyms": [
      "IDEC-Y2B8",
      "IDEC-Y2B8 monoclonal antibody",
      "Y 90 Ibritumomab Tiuxetan",
      "Y 90 Zevalin",
      "Y 90 ibritumomab tiuxetan",
      "YTTRIUM Y-90 IBRITUMOMAB TIUXETAN",
      "Yttrium Y 90 Ibritumomab Tiuxetan",
      "Yttrium Y-90 Ibritumomab Tiuxetan",
      "yttrium Y90 ibritumomab tiuxetan"
    ]
  }
}